SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo - Wikidata - wikimedia - TriplyDB

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

http://www.wikidata.org/entity/Q28362194

about

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists Role of Marine Natural Products in the Genesis of Antiviral Agents The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study Combinatorial approaches to the prevention and treatment of HIV-1 infection An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus HIV-1 Transmission, Replication Fitness and Disease Progression.Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Structural and molecular interactions of CCR5 inhibitors with CCR5.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.New therapeutics that modulate chemokine networks.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.Human retroviruses after 20 years: a perspective from the past and prospects for their future control.New anti-HIV agents and targets.Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.The therapeutic potential of CXCR4 antagonists in the treatment of HIV.

P2860

Q24534620-66F458F5-580C-4EC8-8F9C-9C8127CFBCEE Q24537285-75553EBA-272A-45FA-BC4B-37C16C8A1D74 Q24563937-CC5E211D-3DB9-41F7-BCC2-907C818EEFE4 Q24658283-2FAF9B21-4771-4319-A972-73314D9DC115 Q24802476-0C2F839B-1B4C-4F33-BD3D-E1772125C166 Q26796360-1473A086-1A69-4B25-A3D3-A36F3AC053EE Q27477986-F1C875A0-4DAC-44BC-8D66-24B94875B98B Q28344746-ED6E7774-3D4E-4371-8C51-A525E23B6990 Q28469262-40A5FF73-635E-4513-9D89-7377E1BD04AB Q28477736-2465A797-8D98-4B7B-A765-9DE09C7968F2 Q28481687-CECE4D71-7F08-4B70-B790-B40F1961E950 Q30400060-C68BCDB4-7727-4F64-8045-99FEEC231896 Q33559066-28B00743-9FD9-4FC4-91AA-0F8FD4EB3D6D Q33707328-DB9B1F44-A364-4886-B857-655E3ED77DF8 Q33758570-522B605E-08E3-48DB-BF05-27E2E5F36F84 Q33780620-8E9B4563-DCBE-420B-ABA6-FACF11423D42 Q33781391-9B29DB16-526D-4AB1-B2AB-6E843AC244FB Q33807529-64DE1ADE-E21B-4748-9741-549A4B3483F4 Q33843345-249970A9-B603-406E-8FAD-039CF9AED2AD Q33935348-EA1594C7-99BF-4131-8462-F97AE30153F7 Q33938098-2F6B5D1B-5070-41EA-9513-B9507FCD13C1 Q33938250-662F5748-3B31-4870-9169-6C50D47CDE00 Q33961704-1DD36A9E-8163-4412-B65C-9F3777D93277 Q33984351-504F2561-BA55-48A5-B930-FA3CA857EC0A Q33990552-B7104C43-C539-43E6-9355-7C5C8E0AE1D6 Q34010925-FB902258-2206-4A87-97A5-20EF49B5B16B Q34123595-E69CF8ED-4A3F-4133-BBAC-50BB9E4B0CA7 Q34340428-266B4576-40F0-4956-AD41-B5FC54CB7D35 Q34391721-C5A08DB9-A434-4D02-AF12-E47A0CB44C13 Q34473072-643EA4F8-807E-4A55-BB93-551612236992 Q34494226-630B79DD-9A37-4A63-B5FD-1E7738DAE956 Q34568280-C84858C0-BADC-4764-A13D-0502373D68DE Q34682512-80EAC248-D911-40CE-8440-B7C634996B6A Q34743328-3EF6EB2E-3F0D-4FAC-8528-2C491DB4207F Q34781878-A748615F-22C6-4465-A159-DDA5F70D659C Q34792498-73AA5480-D8D0-4223-BC46-E5309AD0C49A Q34944447-160DBB9D-3DE2-4AC7-8895-7A88D4618511 Q34975941-59F398BF-33E0-43A2-9473-E3E0130B87C6 Q34976806-2ABE2BDD-45F0-4FBA-A710-556BB5CBDE51 Q35056053-082782F9-A0B6-429B-B8C2-E9324CA1BB10

P2860

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

http://www.wikidata.org/entity/Q28362194

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

name

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@ast

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@en

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@nl

type

label

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@ast

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@en

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@nl

prefLabel

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@ast

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@en

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@nl

P1433

Q28362194-906E4156-B4F8-4027-9F0B-1A5DA8496C48

P1476

Q28362194-3F7A2F88-3E9B-46A2-AA4E-7CCEDD400F5B

P2093

Q28362194-0E6E1659-9907-46E8-BB46-2C74A5AE069A

Q28362194-1A21EB5B-AC18-41B0-8AD0-E5AB293B3D8B

Q28362194-1E05465D-D0E2-483B-8360-892F50657987

Q28362194-2AEF54EB-6AD0-4543-865A-AB9C83A5ADE1

Q28362194-2F5F435A-522B-425E-8106-1980218BE2C3

Q28362194-302C6DBE-DABB-41D7-981F-2A2B43C9ECA2

Q28362194-3E3B0361-8832-47C1-8350-31E12ED2733D

Q28362194-47C4D64D-71C1-4E88-B1FF-EDDAE816D4B2

Q28362194-490A9702-548D-4CD1-8B19-C68E0700FD24

Q28362194-504A897A-3BF8-4F28-907C-BE94FB91DEFD

P2860

Q28362194-0D776EFF-C6E7-4152-8DF5-87D4365A5DF4

Q28362194-1363EA01-A463-4517-ADC3-0ECD348CD7C0

Q28362194-16379F6D-E16E-44B6-B804-9DBBF76E0B81

Q28362194-193F27E9-7BE8-409E-8435-07EC39813230

Q28362194-303B165D-6C51-495E-BD8E-B1F02FF193E8

Q28362194-3609D70E-7CAB-4347-A5D0-ABA1B3916835

Q28362194-42E5876F-F4C7-43F0-A246-75AD06698B1E

Q28362194-57896167-B348-436B-9D86-A652FCD41C8C

Q28362194-5C8D93FD-F478-4954-9993-35343E4814D6

Q28362194-5CC15E0E-79EF-455F-B242-4627E9F8B38B

P304

Q28362194-117E2A6D-EF62-4C19-9985-232AB7C10B90

P31

Q28362194-F9290494-2A8A-4B1C-B621-3052C55D06E9

P356

Q28362194-D90015E3-0E3F-4124-8337-5E4E037AA3E3

P407

Q28362194-D97FF289-BF41-4BA3-AA16-0DAD0FEB7D91

P433

Q28362194-50460BAC-EAE3-4203-A974-D7F7A7E474C6

P478

Q28362194-DAA087FD-12CC-48AE-8C1D-E002123E78D3

P577

Q28362194-6F8B2A00-5146-4D13-A9A3-131641140DDD

P5875

Q28362194-7415751A-3B87-4F5E-94A8-7ED9F57DC9AB

P698

Q28362194-0C52641E-3360-4E39-8AED-29D4EAE56EBB

P921

Q28362194-A8CABD6D-FBE4-4E77-9071-56B88FAADD64

P932

Q28362194-85DD497F-E823-4806-A7F1-23C20AB852F8

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

SCH-C (SCH 351125), an orally ...... infection in vitro and in vivo

@en

P2093

A B Fawzi

http://www.w3.org/2001/XMLSchema#string

A Palani

http://www.w3.org/2001/XMLSchema#string

A Trkola

http://www.w3.org/2001/XMLSchema#string

B M Baroudy

http://www.w3.org/2001/XMLSchema#string

C A Stoddart

http://www.w3.org/2001/XMLSchema#string

C C Chou

http://www.w3.org/2001/XMLSchema#string

C Pugliese-Sivo

http://www.w3.org/2001/XMLSchema#string

D D Ho

http://www.w3.org/2001/XMLSchema#string

G R Reyes

http://www.w3.org/2001/XMLSchema#string

J Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a major co-receptor for primary isolates of HIV-1

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

New targets for inhibitors of HIV-1 replication

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

P304

12718-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.221375398

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11743336

http://www.w3.org/2001/XMLSchema#string

P698

11606733

http://www.w3.org/2001/XMLSchema#string

P921

P932

60120

http://www.w3.org/2001/XMLSchema#string